$EW (Edwards Lifesciences Corporation) — investor discussion on X

Five-factor rating: Hold (sector percentile 50.7%)

Graded daily on value C+, growth C+, profitability B+, momentum C, revisions B+. Sector-relative, identical for every user.

Most active credible voices on $EW

@nataninvesting (Natan) — 17 mentions · 38.9K followers
@ewhispers (Earnings Whispers) — 4 mentions · 571.0K followers
@stockmktnewz (Evan) — 4 mentions · 1.2M followers

Recent headlines featuring $EW

2026-10-05: Flávio Bolsonaro leads Lula in Brazil’s first round, forcing Oct. 25 runoff

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $EW are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

$EW (Edwards Lifesciences Corporation) — investor discussion on X

Five-factor rating: Hold (sector percentile 50.7%)

Graded daily on value C+, growth C+, profitability B+, momentum C, revisions B+. Sector-relative, identical for every user.

Most active credible voices on $EW

@nataninvesting (Natan) — 17 mentions · 38.9K followers
@ewhispers (Earnings Whispers) — 4 mentions · 571.0K followers
@stockmktnewz (Evan) — 4 mentions · 1.2M followers

Recent headlines featuring $EW

2026-10-05: Flávio Bolsonaro leads Lula in Brazil’s first round, forcing Oct. 25 runoff

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $EW are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

$EWEdwards Lifesciences Corporation · Medical - Devices · $50.1B

$86.15

-1.2%

Event thread

Key events, in time order

6 items

2026-10-05Company
Edwards Lifesciences to Host Investor Event at TCT
Company confirms Nov 2 investor event; Citi adds EW to 90-day upside catalyst watch
D1 +2.4%
2026-08-298-K filing
8-K: Item 5.02
D1 +0.6% · +5d -4.4%

4 earlier events

2026-07-24 → 07-28EarningsBull
UBS upgrades Edwards Lifesciences to Buy, PT raised to $110
UBS assumes coverage citing TAVR adoption and new growth phase, reinforcing post-Q2 momentum
D1 -1.4% · +5d +4.2%
4 waves of this story
- 2026-07-24 Q2 sales up 13.6% to $1.74B, TAVR +10.5%, FY guidance raised to $6.6-6.9B
- 2026-07-24 Q2 sales $1.74B +12.5% YoY, TAVR $1.3B +10.5%, adj EPS $0.78
- 2026-07-24 Q2 sales $1.74B +12.5% YoY, TAVR $1.3B +10.5%; Piper raises PT to $101
- 2026-07-28 UBS assumes coverage citing TAVR adoption and new growth phase, reinforcing post-Q2 momentum
2026-07-24AnalystBull
Leerink Partners upgrades to Outperform
D1 -1.4% · +5d +4.2%
2026-07-23Earnings
Earnings report
D1 -0.7% · +5d +3.7%
2026-07-238-K filing
8-K: Item 2.02, Item 9.01
D1 -0.7% · +5d +3.7%

Related — this ticker is not the subject

2026-10-05RelatedMacro
Flávio Bolsonaro leads Lula in Brazil’s first round, forcing Oct. 25 runoff
The surprise result came as polls pointed to a tighter race, putting Brazil’s markets and policy outlook in focus.
D1 +2.4%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

6 items

2026-10-05Company
Edwards Lifesciences to Host Investor Event at TCT
Company confirms Nov 2 investor event; Citi adds EW to 90-day upside catalyst watch
D1 +2.4%
2026-08-298-K filing
8-K: Item 5.02
D1 +0.6% · +5d -4.4%
2026-07-24 → 07-28EarningsBull
UBS upgrades Edwards Lifesciences to Buy, PT raised to $110
UBS assumes coverage citing TAVR adoption and new growth phase, reinforcing post-Q2 momentum
D1 -1.4% · +5d +4.2%
4 waves of this story
- 2026-07-24 Q2 sales up 13.6% to $1.74B, TAVR +10.5%, FY guidance raised to $6.6-6.9B
- 2026-07-24 Q2 sales $1.74B +12.5% YoY, TAVR $1.3B +10.5%, adj EPS $0.78
- 2026-07-24 Q2 sales $1.74B +12.5% YoY, TAVR $1.3B +10.5%; Piper raises PT to $101
- 2026-07-28 UBS assumes coverage citing TAVR adoption and new growth phase, reinforcing post-Q2 momentum
2026-07-24AnalystBull
Leerink Partners upgrades to Outperform
D1 -1.4% · +5d +4.2%
2026-07-23Earnings
Earnings report
D1 -0.7% · +5d +3.7%

1 earlier events

2026-07-238-K filing
8-K: Item 2.02, Item 9.01
D1 -0.7% · +5d +3.7%

Related — this ticker is not the subject

2026-10-05RelatedMacro
Flávio Bolsonaro leads Lula in Brazil’s first round, forcing Oct. 25 runoff
The surprise result came as polls pointed to a tighter race, putting Brazil’s markets and policy outlook in focus.
D1 +2.4%

$EW (Edwards Lifesciences Corporation) — investor discussion on X

Five-factor rating: Hold (sector percentile 50.7%)

Most active credible voices on $EW

Recent headlines featuring $EW

$EW (Edwards Lifesciences Corporation) — investor discussion on X

Five-factor rating: Hold (sector percentile 50.7%)

Most active credible voices on $EW

Recent headlines featuring $EW

Edwards Lifesciences to Host Investor Event at TCT

8-K: Item 5.02

UBS upgrades Edwards Lifesciences to Buy, PT raised to $110

Leerink Partners upgrades to Outperform

Earnings report

8-K: Item 2.02, Item 9.01

Flávio Bolsonaro leads Lula in Brazil’s first round, forcing Oct. 25 runoff

Bull vs bear

Discussion

Edwards Lifesciences to Host Investor Event at TCT

8-K: Item 5.02

UBS upgrades Edwards Lifesciences to Buy, PT raised to $110

Leerink Partners upgrades to Outperform

Earnings report

8-K: Item 2.02, Item 9.01

Flávio Bolsonaro leads Lula in Brazil’s first round, forcing Oct. 25 runoff